Anti-Cadherin-17/LI-cadherin antibody

Anti-Cadherin-17/LI-cadherin antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Mouse monoclonal to Cadherin-17/LI-cadherin

IHC-P

Human Cadherin-17 / LI-cadherin / CDH17
No cross-reactivity in ELISA with Human Cad5; Human Cad8; Human E-cad

Cadherin-17 antibody; Cadherin-17 antibody; cdh17 antibody; CDH17 antibody; FLJ26931 antibody; CDH16 antibody; HPT1 antibody; HPT-1 antibody; HPT-1 antibody; HPT-1/LI antibody; LI-cadherin antibody; LI-cadherin antibody; MGC138218 antibody; MGC142024 antibody; RP23-54P14.2 antibody; HPT1 antibody; CDH16 antibody; HPT-1 antibody; HPT-1 antibody; HPT-1/LI antibody

Mouse IgG2b

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human Cadherin-17 / LI-cadherin / CDH17 (rh Cadherin-17 / LI-cadherin / CDH17; Q12864-1; Met1-Met787). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

Monoclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Cadherin-17 or LI-cadherin is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. Cadherin-17/LI-cadherin is a cadherin-like protein consisting of an extracellular region, 7 cadherin domains, and a transmembrane region but lacking the conserved cytoplasmic domain. The protein is a component of the gastrointestinal tract and pancreatic ducts, acting as an intestinal proton-dependent peptide transporter in the first step in oral absorption of many medically important peptide-based drugs. The protein may also play a role in the morphological organization of liver and intestine. Alternative splicing of the encoding gene results in multiple transcript variants. Cadherin-17/LI-cadherin preferentially interact with themselves in a homophilic manner in connecting cells. Cadherin-17 may thus contribute to the sorting of heterogeneous cell types and have a role in the morphological organization of liver and intestine. It's also involved in intestinal peptide transport. Experiments have reported the association between Cadherin-17/LI-cadherin and gastric cancer. Cadherin-17/LI-cadherin expression was detected in 63/94 of gastric adenocarcinomas in addition to intestinal metaplasia. The expression of Cadherin-17 tended to be associated with intestinal type carcinoma, and carcinomas with Cadherin-17 expression was significantly more frequent in advanced stage cases than in early stage. Cadherin-17 is also a useful immunohistochemical marker for diagnosis of adenocarcinomas of the digestive system.

• Liu LX, et al. (2009) Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 50(5): 1453-63.
• Ito R, et al. (2005) Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch. 447(4): 717-22.
• Horsfield J, et al. (2002) Cadherin-17 is required to maintain pronephric duct integrity during zebrafish development. Mech Dev. 115(1-2): 15-26.